Desvenlafaxine in the treatment of major depressive disorder

QR Code

Desvenlafaxine in the treatment of major depressive disorder

Maria Teresa C Lourenco1, Sidney H Kennedy1,21Department of Psychiatry, University Health Network, Toronto; 2Department of Psychiatry, University of Toronto, Toronto, CanadaAbstract: Major depressive disorder (MDD) is among the most incapacitating conditions in the world. The emergence of the select...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Maria Teresa C Lourenco1, Sidney H Kennedy1,2
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2009
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/8043b3d2f9754bdfbcbd3a07a856cddc
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Comparative efficacy of escitalopram in the treatment of major depressive disorder
par: Mazen K Ali, et autres
Publié: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
par: J Craig Nelson, et autres
Publié: (2008)

Levomilnacipran for the treatment of major depressive disorder: a review
par: Asnis GA, et autres
Publié: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
par: Alvarez E, et autres
Publié: (2014)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
par: Aoki A, et autres
Publié: (2014)

Psychiatric comorbidities in patients with major depressive disorder
par: Thaipisuttikul P, et autres
Publié: (2014)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
par: Tobe EH
Publié: (2013)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
par: Low Y, et autres
Publié: (2018)

Major depressive disorder: mechanism-based prescribing for personalized medicine
par: Saltiel PF, et autres
Publié: (2015)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
par: Yang X, et autres
Publié: (2015)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
par: Zhang XF, et autres
Publié: (2015)

Transcranial magnetic stimulation for the treatment of major depression
par: Janicak PG, et autres
Publié: (2015)

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
par: Kitaichi Y, et autres
Publié: (2013)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
par: Singh M, et autres
Publié: (2012)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
par: Bernhard T Baune
Publié: (2008)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
par: Armaly Z, et autres
Publié: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
par: Bojana Perovic, et autres
Publié: (2010)

Is placebo useful in the treatment of major depression in clinical practice?
par: Marchesi C, et autres
Publié: (2013)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
par: Marty Hinz, et autres
Publié: (2010)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
par: Baskaran A, et autres
Publié: (2013)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
par: Han Y, et autres
Publié: (2016)

Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study
par: Fontani V, et autres
Publié: (2011)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
par: Wu MK, et autres
Publié: (2015)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
par: Demir S, et autres
Publié: (2015)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
par: Novick D, et autres
Publié: (2015)

Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders
par: Prasko J, et autres
Publié: (2016)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
par: Berman R, et autres
Publié: (2011)

Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population
par: Kawamura S,&nbsp;Maesawa C,&nbsp;Nakamura K,&nbsp;Nakayama K,&nbsp;Morita M,&nbsp;Hiruma Y,&nbsp;Yoshida T,&nbsp;Sakai A,&nbsp;Masuda T
Publié: (2011)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
par: Gabriel A
Publié: (2013)

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients
par: Koshino Y, et autres
Publié: (2013)

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
par: Michele Fornaro, et autres
Publié: (2011)

Increased expression of retinoic acid-induced gene 1 in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression
par: Haybaeck J, et autres
Publié: (2015)

Case-control association study of ABCB1 gene and major depressive disorder in a local Chinese Han population
par: Xie WW, et autres
Publié: (2015)

Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission
par: Charnsil C, et autres
Publié: (2012)

The structural equation analysis of childhood abuse, adult stressful life events, and temperaments in major depressive disorders and their influence on refractoriness
par: Toda H, et autres
Publié: (2015)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
par: Maneeton B, et autres
Publié: (2018)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
par: Dannehl K, et autres
Publié: (2014)

The cortisol awakening response and major depression: examining the evidence
par: Dedovic K, et autres
Publié: (2015)

Psychomotor retardation and externally oriented thinking in major depression
par: Luca M, et autres
Publié: (2013)

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
par: Robert H Howland
Publié: (2009)